
Previously reported Phase 1 Part 3B interim data demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat, alongside 13.5% placebo-adjusted weight loss and improvements in glycemic control. Read more: bit.ly/4iOmgvC $MTVA
